Evidence map›Paper›PMID 27717258›Full record

ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2016

Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.

Robin M Murray, Harriet Quigley, Diego Quattrone, Amir Englund, Marta Di Forti

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06077292 (Impacts of THC Potency of Cannabis Concentrates and THC Metabolism on Cognitive Impairment in Young Adults), which is not on this map. Cited by 85 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 2 pooled it
41.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06077292 nasuspendednot on this mapstarted 2025, after this paper: background citation

Impacts of THC Potency of Cannabis Concentrates and THC Metabolism on Cognitive Impairment in Young Adults

TypeinterventionalSponsorUniversity of California, San FranciscoRan2025 to 2026Enrolled110ConditionsCannabis Use, THC, Marijuana Use, Cognitive ImpairmentArms15% THC Potency Reduction, 35% THC Potency Reduction
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 306 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Mental health status of the European population and its determinants: A cross-national comparison study.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Robin M MurrayInstitute of Psychiatry, Psychology and Neuroscience, King's College, De Crespigny Park, London, SE5 8AF, UK.
Harriet QuigleyInstitute of Psychiatry, Psychology and Neuroscience, King's College, De Crespigny Park, London, SE5 8AF, UK.
Diego QuattroneInstitute of Psychiatry, Psychology and Neuroscience, King's College, De Crespigny Park, London, SE5 8AF, UK.
Amir EnglundInstitute of Psychiatry, Psychology and Neuroscience, King's College, De Crespigny Park, London, SE5 8AF, UK.
Marta Di FortiInstitute of Psychiatry, Psychology and Neuroscience, King's College, De Crespigny Park, London, SE5 8AF, UK.
King's College London · GB

Funding

Department of Health RP-PG-0606-1049Medical Research Council G0600972Medical Research Council G0700995Medical Research Council G1100583Medical Research Council MR/K004867/1Medical Research Council MR/K013807/1Medical Research Council MR/M008436/1
6 · The paper itself

Abstract

Epidemiological evidence demonstrates that cannabis use is associated with an increased risk of psychotic outcomes, and confirms a dose-response relationship between the level of use and the risk of later psychosis. High-potency cannabis and synthetic cannabinoids carry the greatest risk. Experimental administration of tetrahydrocannabinol, the active ingredient of cannabis, induces transient psychosis in normal subjects, but this effect can be ameliorated by co-administration of cannabidiol. This latter is a constituent of traditional hashish, but is largely absent from modern high-potency forms of cannabis. Argument continues over the extent to which genetic predisposition is correlated to, or interacts with, cannabis use, and what proportion of psychosis could be prevented by minimizing heavy use. As yet, there is not convincing evidence that cannabis use increases risk of other psychiatric disorders, but there are no such doubts concerning its detrimental effect on cognitive function. All of the negative aspects are magnified if use starts in early adolescence. Irrespective of whether use of cannabis is decriminalized or legalized, the evidence that it is a component cause of psychosis is now sufficient for public health messages outlining the risk, especially of regular use of high-potency cannabis and synthetic cannabinoids.

Indexed as

brain structureCannabiscognitive functionearly adolescencegenetic predispositionmarijuanapsychosissynthetic cannabinoids

Identifiers

PMID27717258
PMCPMC5032490
OpenAlexW2522228901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.